E-Mail : info@incozen.com


Beyond Umbralisib, Incozen and its affiliate Rhizen, plans to pursue a two-pronged strategy of commercializing its late-stage pipeline assets in selected developing markets while simultaneously out-licensing for the developed markets.

Incozen is also focussed on building a pipeline of specialty products to target oncology & supportive care indications. Our pipeline will include a mix of

a) late-stage programs with demonstrated clinical POC and well-defined registration path, where we can partner to execute the global trial efficiently & commercialize in our geographies of interest.

b) early-stage programs with demonstrated pre-clinical POC and well-defined IP & commercial potential, where we can in-license or co-develop the asset and commercialize globally.